Ionis, AstraZeneca To Use Real-World Data To Accelerate RNA-Targeting Cholesterol Drug
Phase I Shows Promise, But ION449 Must Catch Up With Inclisiran
Executive Summary
Early data presented at the American Heart Association showed strong PCSK9 and LDL cholesterol lowering for ION449; AstraZeneca plans rapid development under an RWE-based FDA pilot program.
You may also be interested in...
Quick Listen: Scrip’s Five Must-Know Things
Join us for a brief audio tour around the past week's key developments in the global biopharma industry, in this podcast version of Scrip's Five Must-Know Things.
Novartis’ Cholesterol Drug Inclisiran Closes In On EU Approval
Timing means full EU approval could coincide with US FDA authorization later this year.
Ionis Buys Out Akcea As Cardiovascular Pipeline Blooms
The RNA-drug developer, which is buying the approximately 24% of Akcea it doesn't already own for around $500m, highlighted the maturing pipeline in a cardiovascular overview.
Existing Subscriber?
Sign in to continue reading.
Need a specific report? 1000+ reports available
Buy Reports
Need a specific report? 1000+ reports available
Buy Reports